Oral Nemonoxacin in Treating Elderly Patients With CAP

A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia

This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).

Inclusion Criteria:

• Age ≥65 years
• Clinical diagnosis of CAP
• Evidence of inflammatory exudates or infiltrates on chest X-ray

Exclusion Criteria:

• Suspect viral pneumonia, aspiration pneumonia, ventilator-associated pneumonia or hospital-acquired pneumonia
• History of hypersensitivity to quinolone or fluoroquinolone